Fig. 3: Outcomes with T-DXd according to pre-treatment HS-HER2 status. | npj Precision Oncology

Fig. 3: Outcomes with T-DXd according to pre-treatment HS-HER2 status.

From: Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

Fig. 3: Outcomes with T-DXd according to pre-treatment HS-HER2 status.

A Workflow for the quantification of HS-HER2; B TTNT with T-DXd according to HS-HER2 quartiles; C OS with T-DXd according to HS-HER2 quartiles; D TTNT with T-DXd according to HS-HER2 median (HER2-positive disease only); E TTNT with T-DXd in the HS-HER2 cohort according to the traditional HER2 IHC classification of HER2-positive, HER2-low-HER2-0 in the HS-HER2 population. T-DXd trastuzumab deruxtecan, TTNT time to next treatment, HS-HER2 High Sensitivity-HER2, IHC immunohistochemistry, ROI region of interest, OS overall survival.

Back to article page